AC Immune's investment case hinges on its ability to convert its neurodegeneration-focused pipeline into predictable milestone revenue, as demonstrated by the $15.1M recorded in 2026Q2 following a trough of just $338K in 2025Q4—yet this pattern of extreme quarterly volatility (ranging from $338K to $25.5M over ten…
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.16+11.1% vs -$0.18 | $4M+139.2% vs $2M |
Q3 2026 Aug 5, 2026 | $0.03+128.7% vs -$0.10 | $19M-45.2% vs $34M |
Q2 2026 Apr 30, 2026 | -$0.19+5.0% vs -$0.20 | $1M+325.0% vs $329,435 |
Q2 2026 Mar 13, 2026 | -$0.18+5.3% vs -$0.19 | $428,876-70.3% vs $1M |
AC Immune (ACIU) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.
AC Immune announces financial and corporate updates for the quarter ended September 30, 2026, with positive progress across its wholly-owned pipeline.
SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.
AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's disease.
Benchmark ACIU against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AC Immune S.A. (ACIU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.23 | $226.96M | -5.05 | -86.92% | -181.94% | -104.05% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $0.84 | $35.94M | -0.64 | — | — | -685.96% | — | |
| $2.38 | $41.14M | -3.82 | — | -691.81% | — | — | |
| $248.35 | $36.69B | 105.48 | 1.39% | 3.38% | 1.86% | — | |
| $1354.00 | $1.28T | 43.86 | 44.7% | 31.9% | 83.65% | 0.44% |
AC Immune S.A. (ACIU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ACIU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AC Immune S.A. (ACIU) stock FAQ — growth, dividends, profitability & financials explained
AC Immune S.A. (ACIU) reported $19.8M in revenue over the trailing twelve months. Revenue was $3.6M in fiscal year 2025. That is 59% less than the $8.6M of fiscal year 2013.
AC Immune S.A. (ACIU) grew revenue by 353.2% over the trailing twelve months, compared with the twelve months before.
No. AC Immune S.A. (ACIU) reported a net loss of $36.0M over the trailing twelve months.
AC Immune S.A. (ACIU) had a return on equity (ROE) of -104.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
AC Immune S.A. (ACIU) had negative free cash flow of $67.0M in fiscal year 2025.
